



Selenoprotein-p as Biomarker of Selenium Status in Obese Children and Adolescents

Kholoud Gamal Mahmoud ^{a*},
Rasha Mohamed Gamal Elshafiey ^a,
Radwa Mahmoud Elsharaby ^b
and Amany Mahmoud Elbarky ^a

^a Pediatrics Department, Faculty of Medicine, Tanta University, Egypt.

^b Clinical Pathology Department, Faculty of Medicine, Tanta University, Egypt.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/AJPR/2023/v13i4306

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/110208>

Original Research Article

Received: 07/10/2023

Accepted: 12/12/2023

Published: 21/12/2023

ABSTRACT

Background: The child and adolescent obesity have become a major public health problem. Selenoprotein p₁ (SEPP1) is widely acknowledged to be among the most delicate functional indicators of Se status and it plays a role in the metabolism of Se and in anti-oxidative defense. So, we aimed to assess Selenoprotein-p level in obese children and adolescents.

Methods: This cross-sectional comparative work included 60 children: 30 obese children and the control group consisted of 30 children who were healthy and matched in terms of gender and age. A comprehensive taking of history and clinical assessment with anthropometric measurements were conducted on all children and adolescents. Basic investigations and serum selenoprotein-p₁ level were performed.

*Corresponding author: Email: Kholoud.Ismael@med.tanta.edu.eg;

Results: Serum selenoprotein-p₁ (SEPP1) levels were substantially decreased in obese children contrasted to controls.

Conclusions: Selenoprotein p₁ levels were substantially decreased in obese children and adolescent. Selenoprotein p₁ could be a sensitive functional biomarker of selenium status.

Keywords: Obesity; obese children; selenium status; selenoprotein p1.

1. BACKGROUND

Obesity is a worldwide epidemic that is not restricted to adults. Unfortunately, child and adolescents' obesity had become a major public health issue [1]. It is a complex interaction among biological, developmental, behavioral, genetic, and environmental factors [2].

Obesity is strongly associated with multiple comorbidities as insulin resistance (IR), dyslipidemia, cardiovascular disease, diabetes mellitus, hypertension, osteoarthritis, sleep apnea, and stroke [3].

Selenium, denoted by the chemical symbol (Se), is a crucial trace element that was first identified by the Swedish chemist Jons Jacob Berzelius in 1817 [4]. It has antioxidant properties and protective role against oxidative damages [5]. The primary mechanisms by which Se exerts its physiological effects are through the actions of selenoproteins, which are proteins that contain Se in its natural state of selenocysteine. Selenoproteins, including glutathione peroxidases and seleno-protein-p, have been first identified as antioxidants that facilitate the catalytic breakdown of organic hydroperoxides [6].

Selenoprotein p₁ (SEPP1) is widely regarded as among the most sensitive indicators of selenium levels. SEPP1 functions as a Se transporter to maintain antioxidative seleno-enzymes in multiple tissue, and it assumes an essential function in the metabolism of Se and in antioxidative defense. So, a decrease in the expression of SEPP1 and seleno-proteins has been observed to give rise to a range of dysfunctions associated with oxidative stress [7].

2. METHODS

2.1 AIM

TO assess the potential of Selenoprotein-p as a biomarker for evaluating Se levels in children and adolescents with obesity.

2.2 Study Design

This cross-sectional Comparative work was performed between January 2022 to December 2022.

2.3 Study Setting

This work was performed in Pediatrics Department, Tanta University Hospitals, Egypt.

2.4 Study Participants

Individuals in the work had been allocated into 2 groups: Group 1 consisted of 30 obese children according to definition of Centers for Disease Control and Prevention (CDC) with BMI \geq 95th percentile for age and sex, who were collected from clinical nutrition outpatient clinic and Group 2 consisted of A cohort of 30 children who were selected based on their health status, and matched for gender and age who constituted the control group.

Children with Syndromic obesity e.g.; Prader Willi, endocrinal causes of obesity such as Cushing's syndrome, history of drug intake as corticosteroids, history of chronic debilitating diseases, acute inflammatory processes, mental retardation, use of medication that affect; blood pressure, lipid profile, glucose level or causing weight gain and children under special diets or received any vitamins or dietary supplementations within the last 6 months before enrollment in the study; all were excluded from the work. All parents of the participants provided informed permission. The present work received ethical approval from the Ethical committee of the Faculty of Medicine at Tanta University, Egypt. Registration NO: (34888/9/21).

2.5 Study Materials

2.5.1 All children had been exposed to the follows

A. Medical history review: All participants provided a complete medical history, which

included their demographic data, medical, Drug and Family histories, and age at diagnosis.

B. Physical examination: The physical examination included a general condition assessment, system examination, measuring blood pressure. Anthropometric measures, such as height, weight, BMI, waist circumference (WC). The weight was recorded utilizing a Granzia digital weighing scale (PSTG-80, Italy), while the height was determined using a Germany anthropometer (Seca 216). The BMI was calculated as kg/m^2 . The National Centre for Health Statistics' matching growth charts were used to plot the weight, height, BMI measurements and to calculate Z-score (Fryar et al., 2012) and The circumference of the waist results have been displayed on a percentile curve for waist circumference. (Sharma et al., 2015).

C. The following investigations were ordered:

i. **Initial investigations:** Full blood picture, laboratory tests conducted to assess the condition of the liver and kidneys, as well as the serum total lipid profile include measurements of [triglycerides, total cholesterol, HDL, and LDL].

ii. Selenoprotien-p using Enzyme Linked Immuno-Adsorbent Assay (EIISA) by DLdevelop ELISA kit.

2.6 Statistical Analysis

Data was collected using Microsoft Excel for Windows, and the statistical analysis was conducted employing SPSS v26 (IBM Inc., Armonk, NY, USA). Quantitative data was analyzed using the mean and standard deviation (SD), whilst qualitative data was presented using frequencies and percentages.

The statistical tests used for contrasting both groups included Fisher's exact test, the Chi-square test, the Mann-Whitney test, and/or the unpaired Student's t-test, as deemed appropriate. The statistical analysis used Spearman's rank-order correlation to examine the associations among numerical parameters. Statistical significance was set at $p < 0.05$.

3. RESULTS

This study included 60 children, 30 obese children and 30 healthy matched controls with no substantial variation among the two groups as regard to age, sex and residence. The percentage of female obese children was higher than that of male in our study. The demographic information of the groups under the study and their anthropometric measurements are shown in Table 1.




Fig. 1. Correlation Between Selenoprotein P1 and Waist Circumference in Obese Group

Table 1. The demographic data and anthropometric measurements of the studied groups

		Controls (N = 30)	Obese Children (N = 30)	test statistic	p-value
Age of Enrolment (years)	Mean ± SD.	10.07 ± 2.54	10.27 ± 2.59	t = 0.302	0.764
Sex	Female	14 (46.7%)	20 (66.7%)	X ² _{ChS} = 2.443	0.118
	Male	16 (53.3%)	10 (33.3%)		
Residence	Rural	18 (60.0%)	14 (46.7%)	X ² _{ChS} = 1.071	0.301
	Urban	12 (40.0%)	16 (53.3%)		
Family History	Diabetes mellitus	7 (23.3%)	12 (40.0%)	X ² _{ChS} = 1.926	0.165
	Hypertension	5 (16.7%)	11 (36.7%)	X ² _{ChS} = 3.068	0.080
	Obesity	1 (3.3%)	16 (53.3%)	X ² _{ChS} = 18.468	<0.001*
Weight (Kg)	Mean ± SD	36.06 ± 12.04	61.04 ± 18.80	t = 6.130	<0.001*
Weight Z score (SD)	Median [IQR]	0.43	2.29	Z = 6.640	<0.001*
Height (cm)	Mean ± SD	138.28 ± 14.81	143.05 ± 14.34	t = 1.267	0.210
Height Z score (SD)	Median [IQR]	-0.16	0.40	Z = 2.506	0.012*
BMI (Kg/m ²)	Mean ± SD	18.41 ± 2.66	29.18 ± 5.38	t = 9.828	<0.001*
BMI Z score (SD)	Median [IQR]	0.70	2.30	Z = 6.669	<0.001*
Waist circumference (cm)	Mean ± SD	59.17 ± 4.47	87.57 ± 10.15	t = 14.025	<0.001*
Waist circumference centile	Median [IQR]	35.00	96.00	Z = 6.69	<0.001*
		[25.00 -50.00]	[95.00 - 97.00]		

IQR: interquartile range; SD: standard deviation; t: independent samples t-test; Z: Mann-Whitney test; FE: Fisher's exact test; NA: non-applicable; X²_{ChS}: Pearson's Chi-square test for independence of observations; * significant at p<0.05

Table 2. Obesity related data

		N	%
Age of Onset	< 5 years	17	56.7%
	≥ 5 years	13	43.3%
Class of Obesity	Class I	26	86.6%
	Class II	2	6.66%
	Class III	2	6.66%
Clinical Finding	Acanthosis Nigricans	22	73.3%
	Abdominal Enlargement / Striae	3	10.0%
	Acne and Hirsutism	3	10.0%
Blood pressure	Normal BP	26	86.6%
	Pre-hypertension	3	10%
	Stage I hypertension	1	3.4%

N: number

Table 3. The laboratory investigations of the studied groups

		Control (N = 30)	Cases (N = 30)	test statistic	p-value
Hb (gm/dl)	Mean ± SD	11.18 ± 0.96	11.35 ± 0.92	t = 0.671	0.505
PLT	Mean ± SD	307.67 ± 98.29	311.57 ± 92.85	t = 0.158	0.875
TLC	Mean ± SD	6.73 ± 2.08	7.79 ± 2.76	t = 1.682	0.098
AIT (U/L)	Mean ± SD	24.67 ± 3.27	24.13 ± 8.13	t = 0.333	0.740
AST (U/L)	Mean ± SD	22.33 ± 4.24	22.80 ± 6.17	t = 0.342	0.734
Urea (mg/dl)	Mean ± SD	25.03 ± 4.53	23.47 ± 3.53	t = 1.494	0.141
Creat (mg/dl)	Mean ± SD	0.58 ± 0.19	0.53 ± 0.20	t = 0.933	0.354
Total Cholesterol (mg/dl)	Mean ± SD	148.53 ± 16.98	160.80 ± 27.54	t = 2.077	0.043*
HDL (mg/dl)	Mean ± SD	45.03 ± 4.94	48.97 ± 10.70	t = 1.828	0.075
LDL (mg/dl)	Mean ± SD	91.87 ± 12.26	99.13 ± 24.48	t = 1.452	0.154
Triglycerides (mg/dl)	Mean ± SD	77.47 ± 18.40	104.77 ± 26.08	t = 4.685	<0.001*
SEPP (ng/dl)	Median [IQR]	70.35 [65.89 to 77.42]	7.60 [5.82 to 13.99]	Z = 6.653	<0.001*

Z: Mann-Whitney test; SD: standard deviation; t: independent samples t-test; * significant at p<0.05.

The Obese children' weight, BMI, their z -scores and waist circumference were significantly higher than their controls, height (cm) didn't differ significantly between studied groups. However, the corresponding height-z scores had been substantially greater in children with obesity contrasted to controls. Onset of obesity was higher in those aged below 5 years (56.7%) and obese children with class I obesity higher percentage (86.6%) than those with class II (6.66%) and class III (6.66%). Acanthosis nigricans was represented the higher percentage of clinical finding in obese children (73.35%) as shown in Table 2.

Serum triglycerides and total cholesterol had been substantially greater among obese children contrasted to controls; however, no substantial variation was existed in concentrations of HDL, LDL, CBC, Liver and renal function tests between both groups. In contrast to the control group, the Serum SEPP1 was substantially lower in obese children as summarized in Table 3. Also, a substantial negative association was existed among SEPP1 and waist circumference in obese children.

4. DISCUSSION

Child and adolescents' obesity has emerged as an important threat to public health; The modulation of inflammation and oxidative stress was hypothesized, while the micro-nutrient Se has been reported to possess qualities that are anti-inflammatory and anti-oxidative in nature [8].

SEPP1 is Se that contains protein, it is well recognized that this particular functional marker has significant importance in assessing selenium (Se) status. This marker primarily serves as a means of transporting Se, ensuring its delivery to cells and tissues. Furthermore, it plays a crucial role in the metabolism of Se and serves as a key component of the antioxidative defense system [7].

In this regard we evaluate levels of circulation selenoprotein₁ in obese children and adolescents .

As regard to gender in our study, about 66.7% (20) of obese children were female and 33.3% (10) males with Female: male ratio = 2:1. Similarly, Allam and Hamed et al. [9,10] while El-Shafie et al. [11] and Salah et al. [12] studies

showed that prevalence of obesity higher in boys than girls.

Numerous studies have emphasized the need of considering a familial background of obesity, DM, or hypertension when evaluating the health risks associated with obesity among children [13]. In the present work, a substantial variation was existed among participants and controls as regard to family history of obesity ($p < 0.001^*$).

Regarding onset of obesity, our study revealed that obesity is higher prevalence among children less than 5 years, and this agreed with Osei Bonsu and Addo et al. [14] study that showed higher prevalence of obese children below 5 years in Egypt, that may associated with over-nutrient. Our study also showed, higher rate of class I obesity between obese children than class II and III, and this agreed with Twig et al. [15].

In terms of to blood pressure, our work showed about 86.6% of obese children ($n=26$) were with normal BP, 10% of them pre hypertensive (90th - <95th centile for gender and age) ($n=3$) and 3.4% of them were hypertensive (95th centile for gender and age) ($n=1$) and this agreed with Abd-Elghaffar et al. [16] who discovered (8.9%) possess hypertension.

Our work revealed that no substantial variation was existed among obesity in children and controls in SBP and DBP (mmHg) and this agreed with Mohamed et al., [17] study. While Tanaka et al. [18] discovered that obesity in children substantially greater in diastolic and systolic blood pressure contrasted to their controls.

In our study, weight, BMI, and with their corresponding height z-scores, z-scores, waist circumference and waist circumference centile were substantially greater in children with obesity contrasted to controls ($p < 0.001$). This result was in line with Gajewska et al., [19] and López-Peralta et al., [20] that demonstrated significantly higher weight, height, BMI and BMI Z -scores in obese children than controls and they explained that the rapid weight gain in early childhood is often accompanied by an increase in height velocity and advanced bone age.

On other hand Mohammed et al., [21] studies agreed with our results as regard to weight, BMI

and waist circumference, but as regard to height they found no significant difference between obese children and normal weight ($p=0.79$).

As we know acanthosis nigricans is pathognomonic for insulin resistance, we discovered that 22 out of 30 instances (73.33%) showed acanthosis nigricans and this agreed with Sudevan et al., [22] who showed acanthosis nigricans had been observed more in children with obesity (61.5%). Also, Cardenas-Vargas et al., [23] found that acanthosis nigricans was detected in (85.9%) of the children with obesity.

As regards CBC in our study, no significant difference of CBC data was reported between cases and controls and our findings were consistent with Gajewska et al., [24]. However, Emam et al. [25] found that hemoglobin concentrations in children with obesity had been substantially decreased contrasted to were in healthy controls.

The liver seems to be significantly impacted by fat deposition in the presence of obesity. In our work, no substantial variation was existed among obese children and controls in ALT ($p=0.740$) and AST ($p=0.734$) and this agreed with Das et al., [26] and disagreed with the study of Mărginean et al., (2019) who revealed that liver enzymes concentrations had been significant greater in children with obesity contrasted to control ($p<0.001$), ($p=0.03$).

Blood urea and serum creatinine were within normal range with no substantial variations among obese children and controls ($p=0.141$), ($p=0.354$) and this comes in line with the study of Maćkowiak-Lewandowicz et al. [27]. In contrary Khan et al., [28] study revealed that blood urea, serum creatinine was substantially elevated in obese group as contrasted to controls i.e. ($p < 0.01$).

As regard to lipid profile, our study showed that total serum cholesterol and triglycerides (TG) levels had been substantially greater in obese children contrasted to controls ($p=0.043$), ($p<0.001$). while LDL and HDL didn't show substantial variation among both groups ($p=0.154$), ($p=0.075$) and this is agreed with Juliaty and Kurniasih. [29] who found children with obesity had substantially greater TG and cholesterol, in addition to decreased HDL contrasted to normal weight participants. While LDL concentrations hadn't been substantial

various among groups. However, Maćkowiak-Lewandowicz et al., [30] found that obese and control groups didn't vary in serum levels of total cholesterol and LDL. While substantially greater levels of HDL and TG ($p = 0.001$, $p = 0.001$). Ibrahim et al. [31] study reported that no substantial variation in lipid profile among obese children and controls. While Mohammed et al., [21] study found that LDL and serum TC had been substantially greater among children with obesity as contrasted to control. Nevertheless, HDL had been substantially lowered among children with obesity as contrasted to normal-weight one.

There is an elevated frequency of aberrant lipid levels among children and adolescents who are classified as overweight or obese. The prevailing form of dyslipidemia observed in these individuals is characterized by the coexistence of hypertriglyceridemia alongside decreased levels of HDL. This dyslipidemic profile is mostly attributed to underlying insulin resistance [32].

Our study revealed that selenoprotein- p_1 (SEPP1) is substantially decreased among children with obesity contrasted to controls ($p<0.001$) and this in line with Ko et al. [33] study who revealed that Selenoprotein- p_1 concentrations had been decreased in obese children. Also, Sargeant et al. [34] study found that obese (2.81 ± 0.3) had lower SEPP than normal weight (3.01 ± 0.39). Gharipour et al. [35] and Di Giuseppe et al. [36] studies reported that SEPP was inversely relation with BMI. While our results were disagreeing with Chen et al. [37] and El-Kafrawy et al. [38] studies who revealed that selenoprotein- p level higher in obese than their controls but there were performed on adult. Soares de Oliveira et al. [39] found that Excessive adiposity might potentially manifest as a pro-oxidative and pro-inflammatory condition, resulting in an increased demand for selenium and leading to sustained alterations in Se levels over time. Also, our study demonstrated a statistically substantial negative association among serum level of selenoprotein p_1 and waist circumference in obese group and this is agreed with Ko et al. [33] as shown in Fig. 1.

We faced some limitations as the tiny number of subjects participated in our work that also, interfered with subgroup comparison in studied groups.

5. CONCLUSION

Selenoprotein p₁ levels had been substantially decreased in children with obesity and adolescent contrasted to their controls. Selenoprotein p₁ could be a sensitive functional biomarker of selenium status.

CONSENT

As per international standards, parental written consent has been collected and preserved by the author(s).

ETHICAL APPROVAL

The present work received ethical approval from the Ethical committee of the Faculty of Medicine at Tanta University, Egypt. Registration NO: (34888/9/21).

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Jia P, Dai S, Rohli KE, Rohli RV, Ma Y, Yu C, et al. Natural environment and childhood obesity: A systematic review. *Obes Rev.* 2021;22:130-97.
2. Biener AI, Cawley J, Meyerhoefer C. The medical care costs of obesity and severe obesity in youth: An instrumental variables approach. *Health Econ.* 2020;29:624-39.
3. Viitasalo A, Schnurr TM, Pitkänen N, Hollensted M, Nielsen TRH, Pahkala K, et al. Abdominal adiposity and cardiometabolic risk factors in children and adolescents: a Mendelian randomization analysis. *Am J Clin Nutr.* 2019;110:1079-87.
4. Minich WB. Selenium Metabolism and Biosynthesis of Selenoproteins in the Human Body. *Biochemistry (Mosc).* 2022; 87:168-02.
5. Zhong Q, Lin R, Nong Q. Adiposity and Serum Selenium in U.S. Adults. *Nutrients.* 2018;10:124-47.
6. Hariharan S, Dharmaraj S. Selenium and selenoproteins: It's role in regulation of inflammation. *Inflammopharmacology.* 2020;28:667-95.
7. Saito Y. Selenium transport mechanism via selenoprotein P—Its physiological role and related diseases. *Frontiers in Nutrition.* 2021;8:685-517.
8. Abo El-Magd NF, Barbosa PO, Nick J, Covalero V, Grignetti G, Bermano G. Selenium, as selenite, prevents adipogenesis by modulating selenoproteins gene expression and oxidative stress-related genes. *Nutrition.* 2022;93:111-424.
9. ALLAM A, WESAM SM. Revisiting of the epidemiology of obesity among primary school children in Egypt. *Med J Cairo Univ.* 2018;86:3849-57.
10. Hamed AM, Hassan A-EA, Younis MMS, Kamal A-MM. Prevalence of obesity and overweight among primary schools children in Qena, Egypt. *EJHM.* 2019;77: 4899-905.
11. El-Shafie AM, Kasemy ZA, Omar ZA, Alkalash SH, Salama AA, Mahrous KS, et al. Prevalence of short stature and malnutrition among Egyptian primary school children and their coexistence with Anemia. *Ital J Pediatr.* 2020;46:91.
12. Salah NY, Zeid DA, Sabry RN, Fahmy RF, El Abd MA, Awadallah E, et al. Circulating spexins in children with obesity: relation to cardiometabolic risk. *Eur J Clin Nutr.* 2022; 76:119-25.
13. Apperley LJ, Blackburn J, Erlandson-Parry K, Gait L, Laing P, Senniappan S. Childhood obesity: A review of current and future management options. *Clin Endocrinol (Oxf).* 2022;96:288-301.
14. Osei Bonsu E, Addo IY. Prevalence and correlates of overweight and obesity among under-five children in Egypt. *Front Public Health.* 2022;10:1067-522.
15. Twig G, Reichman B, Afek A, Derazne E, Hamiel U, Furer A, et al. Severe obesity and cardio-metabolic comorbidities: a nationwide study of 2.8 million adolescents. *Int J Obes (Lond).* 2019;43: 1391-9.
16. Abdelghaffar S, Hafez M, Shaaban F, Abou Esmail L, Salama S, Rashed R. Resistin and obesity-associated insulin resistance in children. *J Am Sci.* 2010;6: 256-66.
17. Mohamed NS, Maher SE, Abozaid SMM, Moenes HM. Anthropometric and metabolic pattern in obese Egyptian children: its association with C-reactive protein. *Gaz Egypt Paediatr Assoc.* 2020; 68:17.
18. Tanaka M. Improving obesity and blood pressure. *Hypertens Res.* 2020;43:79-89.
19. Gajewska J, Ambroszkiewicz J, Klemarczyk W, Głab-Jabłońska E, Weker

- H, Chelchowska M. Ferroportin-Hepcidin Axis in Prepubertal Obese Children with Sufficient Daily Iron Intake. *Int J Environ Res Public Health*. 2018;15:147-214.
20. López-Peralta S, Romero-Velarde E, Vásquez-Garibay EM, González-Hita M, Robles-Robles LC, Ruiz-González FJ, et al. Bone mineral density and body composition in normal weight, overweight and obese children. *BMC Pediatr*. 2022;22:249.
21. Mohammed A. Hammam M.D. EMES, M.Sc., Rasha M.G. EL-shafiey MD, Amany M. Abo-Elenein, M.D. Determination of Serum Endotoxin Level as an Early Cardiovascular Injury Marker in Obese Children and Adolescents. *The Medical Journal of Cairo University*. 2018;86:3919-26.
22. Sudevan R, Vijay Kumar S, Sunny C, Sunand N, Vasudevan A, S SK, et al. Prevalence of acanthosis nigricans and its association with physical activity in adolescents - School-based analytical cross-sectional study from Kochi, Kerala. *J Family Med Prim Care*. 2021;10:4218-22.
23. Cardenas-Vargas E, Nava JA, Garza-Veloz I, Torres-Castañeda MC, Galván-Tejada CE, Cid-Baez MA, et al. The Influence of Obesity on Puberty and Insulin Resistance in Mexican Children. *Int J Endocrinol*. 2018;2018:7067-292.
24. Gajewska J, Ambroszkiewicz J, Klemarczyk W, Głab-Jabłońska E, Weker H, Chelchowska M. Ferroportin-hepcidin axis in prepubertal obese children with sufficient daily iron intake. *Int J Environ Res Public Health*. 2018;15:147-456.
25. Emam EK, Hamed MH, Fouad DA, Abd-Allah RO. The abnormal iron homeostasis among Egyptian obese children and adolescents: relation to inflammation of obesity. *Egypt J Haematol*. 2018;43:97-102.
26. Das A, Misra P, Panda S. Childhood acanthosis nigricans. *Indian J Pediatr*. 2019;20:147-23.
27. Maćkowiak-Lewandowicz K, Ostalska-Nowicka D, Zachwieja J, Paszyńska E. Differences between obese and non-obese children and adolescents regarding their oral status and blood markers of kidney diseases. *J Clin Med*. 2021;10:147-45.
28. Khan H, Pergulwar A, Siddiqui A, Shinde A. Estimation of serum urea, creatinine and uric acid in obese subjects. *Int J Innov Res Med Sci*. 2017;2:1201.
29. Juliaty A, Kurniasih D. Inflammatory markers and lipid profiles in obese children. *Paediatrica Indonesiana*. 2021;61:271-6.
30. Maćkowiak-Lewandowicz K, Ostalska-Nowicka D, Zachwieja J, Paszyńska E. Differences between obese and non-obese children and adolescents regarding their oral status and blood markers of kidney diseases. *J Clin Med*. 2021;10:147-23.
31. Ibrahim RS, Shaker CW, Mira MF, Sedky MA, Anwar GM. Clinical, laboratory and radiological assessment of skeletal maturation in children and adolescents with obesity. *Egyptian Pediatric Association Gazette*. 2020;68:1-9.
32. Hampl SE, Hassink SG, Skinner AC, Armstrong SC, Barlow SE, Bolling CF, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. *Pediatrics*. 2023;151:147-12.
33. Ko BJ, Kim SM, Park KH, Park HS, Mantzoros CS. Levels of circulating selenoprotein P, fibroblast growth factor (FGF) 21 and FGF23 in relation to the metabolic syndrome in young children. *Int J Obes (Lond)*. 2014;38:1497-502.
34. Sargeant JA, Aithal GP, Takamura T, Misu H, Takayama H, Douglas JA, et al. The influence of adiposity and acute exercise on circulating hepatokines in normal-weight and overweight/obese men. *Appl Physiol Nutr Metab*. 2018;43:482-90.
35. Gharipour M, Sadeghi M, Salehi M, Behmanesh M, Khosravi E, Dianatkah M, et al. Association of expression of selenoprotein P in mRNA and protein levels with metabolic syndrome in subjects with cardiovascular disease: Results of the Selenegene study. *J Gene Med*. 2017;19:14-147.
36. di Giuseppe R, Koch M, Schlesinger S, Borggreffe J, Both M, Müller HP, et al. Circulating selenoprotein P levels in relation to MRI-derived body fat volumes, liver fat content, and metabolic disorders. *Obesity (Silver Spring)*. 2017;25:1128-35.
37. Chen M, Liu B, Wilkinson D, Hutchison AT, Thompson CH, Wittert GA, et al. Selenoprotein P is elevated in individuals with obesity, but is not independently associated with insulin resistance. *Obes Res Clin Pract*. 2017;11:227-32.
38. El-Kafrawy N, Azza E-BM, Abdelsattar S, Zewain SKED. Serum selenoprotein P in lean and obese Egyptian individuals

- and its relation to insulin resistance. Alexandria Journal of Medicine. 2021;57: 61-9.
39. Soares de Oliveira AR, Jayanne Clímaco Cruz K, Beatriz Silva Morais J, Rocha Dos Santos L, Rodrigues de Sousa Melo S, Fontenelle LC, et al. Selenium status and oxidative stress in obese: Influence of adiposity. Eur J Clin Invest. 2021;51:135-38.

© 2023 Mahmoud et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/110208>